Quantinno Capital Management LP Purchases 11,762 Shares of ANI Pharmaceuticals, Inc. $ANIP

Quantinno Capital Management LP lifted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 345.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,167 shares of the specialty pharmaceutical company’s stock after acquiring an additional 11,762 shares during the quarter. Quantinno Capital Management LP owned approximately 0.07% of ANI Pharmaceuticals worth $1,166,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of ANIP. KBC Group NV acquired a new stake in ANI Pharmaceuticals during the 1st quarter valued at $28,000. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals in the first quarter worth $28,000. Hantz Financial Services Inc. grew its holdings in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $48,000. Finally, State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at $50,000. 76.05% of the stock is currently owned by institutional investors.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the sale, the vice president directly owned 74,424 shares of the company’s stock, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the transaction, the senior vice president owned 75,534 shares in the company, valued at approximately $5,816,118. The trade was a 4.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 18,987 shares of company stock valued at $1,546,405. 8.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on ANIP. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Guggenheim decreased their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. Finally, Canaccord Genuity Group reduced their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $105.83.

ANI Pharmaceuticals Stock Up 2.4%

NASDAQ ANIP opened at $76.54 on Friday. The stock has a fifty day moving average of $80.82 and a 200-day moving average of $79.03. The stock has a market capitalization of $1.76 billion, a P/E ratio of 16.50 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 52 week low of $70.15 and a 52 week high of $99.50. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the previous year, the company posted $1.80 earnings per share. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.